Conversely, GLP-1 receptor agonists, such as semaglutide and liraglutide, are more effective in reducing MACE, including myocardial infarction and stroke, making them ideal for patients with atherosclerotic cardiovascular disease or those at high risk for such events. The gene discussed is GLP1R; the disease is myocardial infarction.